Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Stout

Vascular & Interventional Radiology Riverside, CA Medical Doctor

NPI 1679770994 CMS profile 348052

4445 Magnolia Ave, Riverside, CA 92501

Open in the dashboard

General payments

$8,486

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,177 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Charles Stout of Riverside, CA is reported in the CMS Open Payments database as having received $8,486 across 267 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,177 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 75th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,075 56
2024 General $1,421 36
2023 General $1,387 37
2022 General $1,164 46
2021 General $1,415 46
2020 General $548 22
2019 General $476 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Stout
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Charles Stout were reported at $2,075. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Charles Stout Vascular & Interventional Radiology median Middle half National median
2019 $476 $422 $125–$1,555 $163
2020 $548 $200 $68–$652 $114
2021 $1,415 $280 $99–$866 $132
2022 $1,164 $433 $137–$1,497 $149
2023 $1,387 $506 $152–$2,019 $160
2024 $1,421 $556 $175–$1,930 $164
2025 $2,075 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $2,541 103 payments
  2. Medtronic, Inc. $1,877 59 payments
  3. Stryker Corporation $1,756 44 payments
  4. Medical Device Business Services, Inc. $800 2 payments
  5. Penumbra, Inc. $466 32 payments
  6. Route 92 Medical, Inc. $371 2 payments
  7. Viz.Ai, Inc. $299 7 payments
  8. Medtronic USA, Inc. $118 7 payments
  9. Siemens Medical Solutions USA, Inc. $73 1 payment
  10. Smith+Nephew, Inc. $45 3 payments
  11. Other $141 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,686 265 payments
  2. Consulting Fee $800 2 payments
Products named General payments · program years 2019–2025
  1. EMBOTRAP Neurovascular $940 44 payments
  2. EMBOGUARD $917 7 payments
  3. Pipeline $709 25 payments
  4. TARGET $597 12 payments
  5. SOLITAIRE X $527 13 payments
  6. SURPASS EVOLVE $456 10 payments
  7. EMBOTRAP II Revascularization Device $425 15 payments
  8. AXIUM PRIMETM $329 15 payments
  9. Viz.AI LVO $299 7 payments
  10. Embotrap Neurovascular $279 13 payments
  11. Other $2,832 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Diagnostic Radiology: 24

Drug cost

$72

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 14 $72

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$158,759

Medicare's payments for the services billed

Medicare patients

326

Average age 75

Services billed

945

176 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 64%
Arthritis 52%
Chronic kidney disease 48%
Heart failure 46%
Ischemic heart disease 43%
Atrial fibrillation 42%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record